Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 25;48(1):102-110.
doi: 10.3785/j.issn.1008-9292.2019.02.15.

[Advances in molecular mechanism of vascular remodeling in pulmonary arterial hypertension]

[Article in Chinese]
Affiliations
Review

[Advances in molecular mechanism of vascular remodeling in pulmonary arterial hypertension]

[Article in Chinese]
Li Xiao et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. .

Abstract

Pulmonary arterial hypertension (PAH) is a clinical hemodynamic syndrome characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance leading to right heart failure and death. Vascular remodeling is the most prominent histopathological feature of PAH, which is regulated by many factors. Endoplasmic reticulum stress, calcium disorder and mitochondrial dysfunction are involved in the vascular cell proliferation and apoptosis by regulating intracellular calcium homeostasis and cellular metabolism. Epigenetic phenomenon such as DNA damage and abnormal expression of miRNA are also involved in the regulation of abnormal proliferation of vascular cells. Vascular cell phenotype switching including endothelial-mesenchymal transition and smooth muscle cell phenotype switching play an important role in abnormal proliferation of vascular cells. Vascular remodeling is produced by a variety of cells and molecular pathways, and aiming at multiple targets which is expected to find a new breakthrough in the treatment of PAH,and to improve abnormal vascular remodeling, delay or even reverse the progression of PAH.

肺动脉高压(PAH)是以肺动脉压和肺血管阻力升高为特征的临床血流动力学症候群,可导致右心衰竭和死亡。血管重构是PAH最显著的组织病理学特征,其形成受多方面因素的调控。内质网应激、钙紊乱和线粒体功能紊乱通过调节细胞内钙稳态和细胞代谢调控血管细胞的增殖凋亡能力;表观遗传学现象(如DNA损伤和微小RNA表达异常)参与调控血管细胞的异常增殖;血管细胞表型转化(包括内皮细胞间质转化和平滑肌细胞表型转换)是引起血管细胞异常增殖的重要原因。血管重构由多种细胞和分子通路共同作用产生,针对多靶点来改善PAH中发生的异常血管重构,进而延缓甚至逆转PAH的进程,有望成为PAH治疗上新的突破口。

PubMed Disclaimer

Figures

None
图1
内皮细胞间质转化过程示意图

Similar articles

Cited by

References

    1. YUAN J X, RUBIN L J. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation. 2005;111(5):534–538. - PubMed
    1. VONK NOORDEGRAAF A, GROENEVELDT J A, BOGAARD H J. Pulmonary hypertension. Eur Respir Rev. 2016;25(139):4–11. - PMC - PubMed
    1. MCGOON M D, BENZA R L, ESCRIBANO-SUBIAS P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62:D51–D59. - PubMed
    1. YEAGER M E, BELCHENKO D D, NGUYEN C M, et al. Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2012;46(1):14–22. - PMC - PubMed
    1. YEAGER M E, REDDY M B, NGUYEN C M, et al. Activation of the unfolded protein response is associated with pulmonary hypertension. Pulm Circ. 2012;2(2):229–240. - PMC - PubMed